Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History


Sector: Healthcare | Sub-Sector: Diagnostics & Research
Alternate Symbol(s): DIAGF

Spectral Diagnostics Inc operates in the in-vitro diagnostic testing market. The Company focuses on the development of diagnostic tests that provide critical information for the early identification of life-threatening disease.
Price: $0.345 | Change: +$0.03 | % Change: +9.52%
Volume: 1.1m | Day High/Low: 0.345/0.29 | 52 Week High/Low: 0.77/0.18


Last Traded: April 17, 2014 11:59 Transaction Volume: 1.1m
Open: $0.345 Previous Close: $0.315
Bid: $0.315 Ask: $0.345
Bid Size: 5,000 Ask Size: 5,000
Market Cap: $46.4m Shares Out: 134.5m
PE Ratio: N/A Dividend Yield: N/A
Scale: 1d 5d 3m 6m 1y 2y 5y
Type: Line Area OHLC

Advanced Charts

Latest News

Spectral Diagnostics (T.SDI) jumps 24% on EUPHRATES trial update

Spectral Diagnostics (T.SDI) announces completion of Data Safety Monitoring Board trial on EUPHRATES and shares gain 24%

Gaalen Engen   6 days ago
0 stars

Spectral Updates Status Of EUPHRATES Trial

Canada NewsWire   6 days ago
0 stars

Spectral announces fourth quarter and fiscal 2013 results

Canada NewsWire   March 27, 2014
0 stars

Spectral Diagnostics Provides Clinical Update on the Euphrates Trial

Canada NewsWire   March 11, 2014
0 stars

Spectral Diagnostics Announces Extension of Warrants

Canada NewsWire   February 24, 2014
0 stars


Canadian Biotech comes back to life: A buyer's guide

Everything you could ever want to know about biotech, biomed and bio investments up north.

Tony Pullen   January 21, 2014
0 stars

Mystery Movers: Biomed shares surging, triple digit rises all over, executives baffled

When you're standing on a launchpad and a rocket is taking off, the best place to be is on the rocket.

Chris Parry   November 19, 2013
0 stars

Mystery Movers: Spectral Diagnostics jumps 22% as Canadian biotech goes viral

You're still looking for rocks in the ground? Get with the program: Biotech is booming.

Chris Parry   November 5, 2013
0 stars

Rare earth junior could have another good year ... or two

Plus being close to throwing in the towel on this tiny biotech play

Danny Deadlock   February 7, 2011
0 stars

Latest Bullboard Posts

  • RE:Excellent post Square

    5 stars

    Hey Schemer/Square, What do you think the chances are that Spectral will do the same as Medwell, doing a reverse split (1 for 4?). I know...

    2.5 stars

  • Excellent post Square

    2.5 stars

    You make some good points Nohandles, but I'm counting on you being very wrong on the lowball financing, allow me to make my points; A...

    2 stars

  • RE:Don't feel too bad Gramma...

    5 stars

    Shares outstanding and fully diluted share count are two very different things.  Let me know when you get a grasp of this super complex...

    2 stars

  • Don't feel too bad Gramma...

    1 star

    BIG #'s can challenge us all. You've managed to add 50 Million to the current share count. I might suggest removing the zeros when you...

    2 stars

  • RE:RE:750 MIL annual revenue

    3 stars

    Wedbush isn't predicting a "lowball" financing, so why in the world would you?  I mean aside from an agenda driven rationale of course...

    2 stars